ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

524
Analysis
Health Care • South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
•22 Jan 2026 09:55•Broker

Mirae Asset Minutes [2026: Volume 2]Biweekly Strategy Meeting Recap

Driven by surging power demand from data centers, new capacity additions are accelerating across large-scale nuclear power plants, SMRs, and gas...

Logo
172 Views
Share
•18 Jan 2026 08:30

APAC Healthcare Weekly (January 18) – ImmuneOnco, Wuxi Bio, Eisai, Daiichi, SK Biopharm, HK Inno.N

ImmuneOnco got trial approval for atherosclerosis drug candidate, timdarpacept in China. Eisai secures rights to NSCLC drug taletrectinib. HK inno...

Logo
411 Views
Share
•08 Jan 2026 08:04•Broker

Mirae Asset Minutes [2026: Volume 1]Biweekly strategy meeting recap

Hyundai Motor Group (HMG) is set to announce its AI robotics strategy on Jan. 6 and is expected to appoint an advanced vehicle platform division...

Logo
182 Views
Share
bullish•Samsung C&T
•01 Oct 2026 07:51

Korean Holdcos Vs Opcos Gap Trading Opportunities in 4Q 2026

In this insight, I highlight the recent pricing gap divergences of the major Korean holdcos and opcos which could provide trading opportunities in...

Logo
146 Views
Share
•11 Dec 2025 03:25•Broker

Mirae Asset Minutes [2025: Volume 23]Biweekly strategy meeting recap

While rising memory prices could modestly weigh on global IT device sales in 2026, we note that memory chips’ share of smartphone BoM costs is only...

Logo
261 Views
Share
x